Edition:
United Kingdom

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

7.50USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$7.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
49,826
52-wk High
$10.24
52-wk Low
$2.43

Chart for

About

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare... (more)

Overall

Beta: 2.59
Market Cap(Mil.): $130.07
Shares Outstanding(Mil.): 20.84
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Dicerna Announces First Human Dosed In Phase 1 Clinical Trial Of DCR-PHXC

* DICERNA ANNOUNCES FIRST HUMAN DOSED IN PHASE 1 CLINICAL TRIAL OF DCR-PHXC FOR TREATMENT OF ALL FORMS OF PRIMARY HYPEROXALURIA

07 Dec 2017

BRIEF-Dicerna Pharmaceuticals Q3 loss per share ‍$0.92

* Q3 2017 loss per share ‍$0.92 Source text for Eikon: Further company coverage:

02 Nov 2017

BRIEF-Boehringer, Dicerna collaborate to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis

* Boehringer Ingelheim and Dicerna announce collaboration to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis (NASH)

02 Nov 2017

BRIEF-Dicerna files clinical trial application for DCR-PHXC for phase 1 study in hyperoxaluria

* Dicerna files clinical trial application for DCR-PHXC, the company’s most advanced GalXC™ product candidate, for phase 1 study in primary hyperoxaluria (ph)

16 Oct 2017

BRIEF-Dicerna Q2 net loss per share $1.15

* Dicerna reports second quarter 2017 financial and operating results and provides corporate update

10 Aug 2017

Earnings vs. Estimates